Literature DB >> 28858175

Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.

Aikaterini Tsiogka1, Gerhard L Jansky, Johann W Bauer, Peter Koelblinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28858175     DOI： 10.1097/CMR.0000000000000384

Source DB:  PubMed          Journal:  Melanoma Res        ISSN： 0960-8931            Impact factor:   3.599


× No keyword cloud information.
  16 in total

Review 1.  Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors:  Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

Review 2.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 3.  Time to dissect the autoimmune etiology of cancer antibody immunotherapy.

Authors:  Michael Dougan; Massimo Pietropaolo
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 4.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

Review 5.  Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.

Authors:  V Lo Preiato; S Salvagni; C Ricci; A Ardizzoni; U Pagotto; C Pelusi
Journal:  Rev Endocr Metab Disord       Date:  2021-01-06       Impact factor: 6.514

6.  New-onset insulin-dependent diabetes due to nivolumab.

Authors:  Ali A Zaied; Halis K Akturk; Richard W Joseph; Augustine S Lee
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-03-28

7.  Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome.

Authors:  Giulia Lanzolla; Alberto Coppelli; Mirco Cosottini; Stefano Del Prato; Claudio Marcocci; Isabella Lupi
Journal:  J Endocr Soc       Date:  2019-01-08

8.  Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.

Authors:  Jeroen M K de Filette; Joeri J Pen; Lore Decoster; Thomas Vissers; Bert Bravenboer; Bart J Van der Auwera; Frans K Gorus; Bart O Roep; Sandrine Aspeslagh; Bart Neyns; Brigitte Velkeniers; Aan V Kharagjitsingh
Journal:  Eur J Endocrinol       Date:  2019-09       Impact factor: 6.664

9.  Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.

Authors:  Tomoko Kobayashi; Shintaro Iwama; Yoshinori Yasuda; Norio Okada; Taku Tsunekawa; Takeshi Onoue; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Yoshiaki Morishita; Motomitsu Goto; Hidetaka Suga; Ryoichi Banno; Kenji Yokota; Tetsunari Hase; Masahiro Morise; Naozumi Hashimoto; Masahiko Ando; Hitoshi Kiyoi; Momokazu Gotoh; Yuichi Ando; Masashi Akiyama; Yoshinori Hasegawa; Hiroshi Arima
Journal:  J Endocr Soc       Date:  2018-02-06

10.  Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy.

Authors:  Taha Alrifai; Faisal Shaukat Ali; Sameer Saleem; Diana Carolina Miranda Ruiz; Dana Rifai; Sundas Younas; Faisal Qureshi
Journal:  Case Rep Oncol Med       Date:  2019-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.